Prostate cancer cells survive anti‐androgen and mitochondrial metabolic inhibitors by modulating glycolysis and mitochondrial metabolic activities
Abstract
Most cancer cells are more glycolytic even under aerobic conditions compared with their normal counterparts. Recent evidence of tumor cell metabolism, however, shows that some tumors also increase mitochondrial oxidative phosphorylation (ox‐phos) at some disease states during progression and/or development of drug resistance. Our data show that anti‐androgen enzalutamide (ENZA) resistant prostate cancer (PCa) cells use more mitochondrial metabolism leading to higher ox‐phos as compared to the ENZA‐sensitive cells and can become vulnerable to mitochondrial metabolism targeted therapies.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jun 25, 2021
- Source ID
- 10.1002/pros.24146
Entities
People
- Amado Zurita
- Evan N. Cohen
- George Wilding
- Hirak S. Basu
- James M. Reuben
- Lian‐chun Xiao
- Mark Titus
- Nathaniel Wilganowski
- Samantha Robertson
- Sumankalai Ramachandran
Organizations
- Congressionally Directed Medical Research Programs
- University of Texas at Austin